Compare Moderna, Inc. (MRNA) vs Verizon Communications Inc (VZ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs Verizon Communications Inc — how do they compare? Moderna, Inc. trades at $208.4 (market cap $78.65B), while Verizon Communications Inc trades at $41.15 (market cap $192.57B). The key difference: Verizon Communications Inc is far larger — about 2.4× Moderna, Inc.'s market cap, and Verizon Communications Inc pays a 6.11% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Moderna, Inc. for 59 Days and Verizon Communications Inc for 109 Days on average.
| MRNA | VZ | |
|---|---|---|
Market Cap | $78.65B | $192.57B |
Volume | 37,373,437 | 20,940,094 |
Sector | Health | Media |
52-Week High | $203.46 | $51.45 |
52-Week Low | $22.36 | $38.40 |
Typical Hold Time | 59 Days | 109 Days |
Enterprise Value | $74.80B | $379.28B |
Dividend Yield | — | 6.11% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $196.48, up 4.81% with strong technical momentum as it joins the Nasdaq-100 index. Despite recent earnings beats, the company faces fundamental challenges with revenue declining from $18.9B in 2022 to $1.92B in 2025 and negative net income margins exceeding -140%. The stock's 500% rally in 2026 has pushed valuations to elevated levels with P/S ratio of 35.08, creating divergence between technical strength and financial fundamentals.
While Nasdaq inclusion and cancer vaccine pipeline progress offer catalysts, Moderna faces significant execution risks amid declining COVID revenue and high valuation multiples. Analyst consensus remains cautious with only 28% buy ratings and $115.70 price target well below current levels, suggesting limited near-term upside despite technical bullish signals.
Verizon (VZ) trades at $41.115, down 10.17% over the past day, reflecting recent market pressure. The stock shows a bearish technical signal with key support at $45. Fundamentally, VZ maintains solid profitability with a 59.26% gross margin and has beaten earnings estimates in recent quarters. The company generates strong operating cash flow of $37.14 billion (2025) and offers a consistent dividend, with recent payouts of $0.71 per share. Analyst consensus is a 'Hold' with a $48.17 price target, indicating potential upside from current levels.
The outlook for VZ hinges on execution in the competitive telecom sector. Opportunities include stable cash flow supporting dividends and joint ventures expanding coverage. Risks involve high debt levels, with total debt at $144.01 billion, and pressure from rivals like T-Mobile. Earnings on October 26, 2026, will be critical for confirming growth trends amid economic uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About Verizon Communications Inc
Verizon Communications Inc. is an integrated telecommunications company that provides wire line voice and data services, wireless services, Internet services, and published directory information. The Company also provides network services for the federal government including business phone lines, data services, telecommunications equipment, and payphones.
Read more on VZ →
